Stampfer M R, Garbe J, Levine G, Lichtsteiner S, Vasserot A P, Yaswen P
Lawrence Berkeley National Laboratory, Life Sciences Division, Berkeley, CA 94720, USA.
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4498-503. doi: 10.1073/pnas.071483998. Epub 2001 Apr 3.
Failures to arrest growth in response to senescence or transforming growth factor beta (TGF-beta) are key derangements associated with carcinoma progression. We report that activation of telomerase activity may overcome both inhibitory pathways. Ectopic expression of the human telomerase catalytic subunit, hTERT, in cultured human mammary epithelial cells (HMEC) lacking both telomerase activity and p16(INK4A) resulted in gaining the ability to maintain indefinite growth in the absence and presence of TGF-beta. The ability to maintain growth in TGF-beta was independent of telomere length and required catalytically active telomerase capable of telomere maintenance in vivo. The capacity of ectopic hTERT to induce TGF-beta resistance may explain our previously described gain of TGF-beta resistance after reactivation of endogenous telomerase activity in rare carcinogen-treated HMEC. In those HMEC that overcame senescence, both telomerase activity and TGF-beta resistance were acquired gradually during a process we have termed conversion. This effect of hTERT may model a key change occurring during in vivo human breast carcinogenesis.
无法对衰老或转化生长因子β(TGF-β)作出生长停滞反应是与癌症进展相关的关键紊乱现象。我们报告称,端粒酶活性的激活可能会克服这两种抑制途径。在缺乏端粒酶活性和p16(INK4A)的培养人乳腺上皮细胞(HMEC)中,人端粒酶催化亚基hTERT的异位表达导致细胞在有无TGF-β的情况下都获得了维持无限生长的能力。在TGF-β存在的情况下维持生长的能力与端粒长度无关,并且需要能够在体内维持端粒的具有催化活性的端粒酶。异位hTERT诱导TGF-β抗性的能力可能解释了我们之前所描述的,在经致癌物处理的罕见HMEC中内源性端粒酶活性重新激活后出现的TGF-β抗性增加现象。在那些克服了衰老的HMEC中,端粒酶活性和TGF-β抗性都是在一个我们称为转化的过程中逐渐获得的。hTERT的这种作用可能模拟了人类乳腺肿瘤发生过程中发生的一个关键变化。